FluoGuide (FLOU) Q4 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with a new strategic partnership, clinical progress for FG001, and a successful SEK 60 million capital raise.

• FG001 demonstrated efficacy and safety in Phase II trials for brain and head and neck cancers, with expanded therapeutic potential.

• Partnership with Intuitive Surgical aims to integrate FG001 with robotic-assisted surgery, broadening treatment options.

• Strengthened management team to support late-stage clinical development and commercialization.

Financial highlights

• No revenue reported for Q4 or full year 2024; net loss of DKK 8.7 million in Q4 and DKK 29.0 million for the year, both improved from prior year.

• EBIT for 2024 was DKK -33.0 million, up from DKK -43.9 million in 2023.

• Cash position at year-end was DKK 18.6 million, with an undrawn SEK 40 million credit facility.

• Solvency ratio increased to 81% from 43% year-over-year.

• Result per share improved to DKK -2.23 from DKK -3.22 year-over-year.

Outlook and guidance

• 2025 milestones include FDA consultations for brain cancer, first patient enrollment in head and neck Phase II trial, and interim data readouts.

• Plans to expand FG001 indications and pursue additional partnerships, with long-term goals of first approvals in the US and head and neck cancer markets.